Sanofi ADR (NASDAQ: SNY) has a higher price-to-earnings ratio of 29.49x compared to its average ratio. SNY has 36-month beta value of 0.56. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for SNY is 2.50B, and currently, short sellers hold a 0.21% ratio of that float. The average trading volume of SNY on February 05, 2025 was 2.47M shares.
SNY) stock’s latest price update
Sanofi ADR (NASDAQ: SNY)’s stock price has gone rise by 0.28 in comparison to its previous close of 53.35, however, the company has experienced a 1.00% increase in its stock price over the last five trading days. businesswire.com reported 2025-02-04 that MASSY, France–(BUSINESS WIRE)–MITEM PHARMA, a French-based pharmaceutical company dedicated to Drugs of Major Therapeutic Interest (DMTI), is pleased to announce that it has acquired the rights to FLISINT®, an infectious disease DMTI, from SANOFI WINTHROP INDUSTRIE (Gentilly – France). FLISINT® (fumagillin) is recognised as the only treatment capable of overcoming Enterocytozoon bieneusi microsporidia infections. This opportunistic germ develops in clinical situations of immunosuppression (e.
SNY’s Market Performance
Sanofi ADR (SNY) has experienced a 1.00% rise in stock performance for the past week, with a 11.02% rise in the past month, and a 1.17% rise in the past quarter. The volatility ratio for the week is 1.52%, and the volatility levels for the past 30 days are at 1.38% for SNY.. The simple moving average for the past 20 days is 4.25% for SNY’s stock, with a 4.29% simple moving average for the past 200 days.
Analysts’ Opinion of SNY
Argus, on the other hand, stated in their research note that they expect to see SNY reach a price target of $60, previously predicting the price at $55. The rating they have provided for SNY stocks is “Buy” according to the report published on July 26th, 2024.
Morgan Stanley gave a rating of “Equal-Weight” to SNY, setting the target price at $55 in the report published on January 23rd of the previous year.
SNY Trading at 8.42% from the 50-Day Moving Average
After a stumble in the market that brought SNY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.28% of loss for the given period.
Volatility was left at 1.38%, however, over the last 30 days, the volatility rate increased by 1.52%, as shares surge +11.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.46% upper at present.
During the last 5 trading sessions, SNY rose by +1.00%, which changed the moving average for the period of 200-days by +16.03% in comparison to the 20-day moving average, which settled at $51.32. In addition, Sanofi ADR saw 10.93% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for SNY
Current profitability levels for the company are sitting at:
- 0.22 for the present operating margin
- 0.68 for the gross margin
The net margin for Sanofi ADR stands at 0.08. The total capital return value is set at 0.13. Equity return is now at value 7.58, with 4.44 for asset returns.
Based on Sanofi ADR (SNY), the company’s capital structure generated 0.25 points at debt to capital in total, while cash flow to debt ratio is standing at 0.34. The debt to equity ratio resting at 0.33. The interest coverage ratio of the stock is 7.44.
Currently, EBITDA for the company is 12.0 billion with net debt to EBITDA at 1.51. When we switch over and look at the enterprise to sales, we see a ratio of 2.44. The receivables turnover for the company is 6.76for trailing twelve months and the total asset turnover is 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.46.
Conclusion
To put it simply, Sanofi ADR (SNY) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
